GENE ONLINE|News &
Opinion
Blog

Spinal Muscular Atrophy
Genentech Unveils Positive Two-Year Data For Spinal Muscular Atrophy Drug
2022-10-13
Novartis Reported Two Deaths Following Zolgensma Gene Therapy
2022-08-12
First Oral SMA Drug by Roche Now Available to Newborns
2022-06-01
After FDA Lifts Hold, Novartis to Proceed with Clinical Trials for Expensive Rare Disease Therapy
2021-08-04
Novartis’ Expensive Gene Therapy for SMA Reasserts its Efficacy in Two Clinical Trials
2021-06-24
Jaguar Launches with a Pre-clinical Pipeline of AAV9-Based Gene Therapies
2021-02-28
R&D
Altering the Treatment Landscape of Neurodegenerative Diseases Using Antisense Oligonucleotides (ASOs)
2020-08-17
Genentech Enters Spinal Muscular Atrophy Market with Risdiplam’s FDA Approval
2020-08-11
Spotlight: New Gene Therapies on the Horizon for the Treatment of Neurogenetic Diseases
2020-08-03
Spotlight: Roche’s SMA Drug, Risdiplam Makes Strong Case for Regulatory Approval
2020-07-05
R&D
Biogen’s SMA Drug, Spinraza Continues to Show Benefits in Pre-Symptomatic Patients
2020-06-14
R&D
Weekly Cover: Eisai to Launch “NouKNOWTM” in Japan for Regular Self-assessment of Brain Health
2020-03-26
FDA Okays Expensive Gene Therapy for Infantile-Onset Spinal Muscular Atrophy
2019-05-29
LATEST
Innovative Cellular Mapping of BRCA-Related Breast Cancer Findings Reveals Novel Therapeutic Targets
2024-03-29
Previewing AACR 2024 With Select Pre-Meeting Highlights
2024-03-28
Roche Delivering on Malaria Screening Solutions for Blood Donation
2024-03-28
Innovating Cancer Treatment: The Role of ADC Technology at Nona Biosciences
2024-03-28
BIO CHINA 2024 Brings Biotech Experts and Industry Elites Together for Innovation
2024-03-27
Galderma’s Strong European IPO Debut
2024-03-26
Markets and Mergers: Boston Scientific and Axonics Shake Hands on Deal
2024-03-25
EVENT
2024-04-06
Biotech Innovation Funding Networking
Los Angeles, USA
Scroll to Top